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Abstract: Gut microbiota colonization is a complex, dynamic, and step-wise process that is in
constant development during the first years of life. This microbial settlement occurs in parallel with
the maturation of the immune system, and alterations during this period, due to environmental and
host factors, are considered to be potential determinants of health-outcomes later in life. Given that
host–microbe interactions are mediated by the immune system response, it is important to understand
the close relationship between immunity and the microbiota during birth, lactation, and early infancy.
This work summarizes the evidence to date on early gut microbiota colonization, and how it influences
the maturation of the infant immune system and health during the first 1000 days of life. This review
will also address the influence of perinatal antibiotic intake and the importance of delivery mode and
breastfeeding for an appropriate development of gut immunity.
Keywords: gut microbiota; postnatal immune development; gut immunity; breastfeeding;
probiotics; antibiotics
1. Introduction
Epidemiological studies highlight the relevance of the period from conception to early life in
the physiological and structural patterns of infant development, affecting their potential “health
programming”. The fetus adapts to the intrauterine environment, being able to alter its metabolism in
response to external stimuli. The physiological and metabolic adaptations that the fetus undergoes in
response to those stimuli could produce permanent changes in the host, which may lead to a higher
risk of developing diseases and/or disorders, such as obesity, allergies, diabetes, or cardiovascular
diseases, in adult life [1].
The first 1000 days after conception (including the pregnancy period and the first two years of
life), which are considered a “window of opportunity”, are crucial for the development and health of
the future adult, as well as key to the establishment of the intestinal microbiota and immune system
maturation. The physiological and immune development of the infant and the establishment of their
microbiota occur in parallel throughout this short space of time. This microbiota plays a central role in
health, intervening in key host metabolic and immunological functions.
DEFINITIONS
Microbiota: the microbial community in a specific niche/environment.
Microbiome: the total genomic repertoire of a microbial community (microbiota).
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2. Prenatal Microbial Exposure and Mother–Fetus Immune Interaction
Recent studies have shown that the physiologic, immune, and metabolic changes that occur
during pregnancy run in parallel with variations in microbial composition and diversity in the maternal
microbiota [2–4]. During gestation, the maternal immune system adapts to the required tolerance
between mother and fetus, although the microbiota–immune system interaction during pregnancy has
been poorly described. Moreover, maternal conditions, including pre-gestational body mass index [5],
weight gain during pregnancy [6], various diseases, such as gestational diabetes [7] or allergy [8,9],
and especially antibiotic consumption [10] may affect the microbiota composition of the mother and
newborn. However, the relevance of the shifts that these conditions may provoke in the immune
system development is still unclear. Despite the importance of diet on the adult the microbiota,
only a few studies [11–13] have investigated how the microbiota of pregnant women affect newborn
colonization or its relation to immune system maturation.
It has been suggested that the maternal microbiota and its metabolites transferred to the fetus
may play a key role in a newborn’s preparation for optimal host–microbe interactions, thus influencing
infant immune responses [14]. In this scenario, the maternal gestational environment is critical for
fetal physiology and development, inducing long-lasting and/or permanent modifications that may
imprint a specific hallmark on the fetus, leading to an increased risk of developing non-communicable
diseases later in life [1].
It has been suggested that that microbial contact may start before birth, although this hypothesis
is still controversial. The original idea that the fetus resides in a sterile environment has being
challenged [15], primarily by the presence of viable bacteria in the meconium [16–19], thus reflecting a
potential in utero microbial environment, and also by the presence of bacteria and bacterial DNA in
the maternal–fetal interphase. A few studies have examined the potential bacterial transmission
through the placental barrier in healthy term pregnancies, analyzing umbilical cord [20], fetal
membranes [21,22], and amniotic fluid [21,23] from healthy neonates. Indeed, a strong correlation
between intrauterine infections and preterm deliveries has been reported, and remarkably, most of the
bacteria detected in these infections are common habitants of the vaginal tract [24,25]. Nevertheless, it
has to be kept in mind that the bacterial load in the fetal environment has been estimated to be
extremely low, facilitating the possibility for (environmental) contamination of the studied samples.
Thus, some authors consider that the placenta and amniotic fluid are sterile [26,27].
The bacteria that have been detected in meconium include Enterococcus and Escherichia and
partly resemble the maternal and infant gastrointestinal tract microbiota [16,19]. Maternal microbial
transmission has been explored in an animal study where genetically-labelled Enterococcus faecium,
administered to pregnant mice were found in the meconium [16]. However, the mechanisms by
which gut bacteria enter the uterine environment need further investigation, especially in humans,
where both technical and ethical difficulties are encountered. Nevertheless, it has been speculated
that the bacteria might access the bloodstream and travel to the placenta through translocation of
the gut epithelium, presumably accompanied by dendritic cells, as shown in mice models [28,29].
Some mechanisms have been proposed for the microbiota spreading, including migration from the
vagina or hematogenous spread from the gut and oral microbiota [30]. In human studies, the placental
microbiota has been described to resemble the human oral microbiota more than the vaginal, fecal, skin,
or nasal microbiota, hosting non-pathogenic commensal microbiota from the Firmicutes, Tenericutes,
Proteobacteria, Bacteroidetes, and Fusobacteria phyla [31]. Speculatively, the microbiota here is
established via the hematogenous spread of oral microbiota, likely during early vascularization and
placentation. Moreover, oral cavity bacteria have also been isolated from the amniotic fluid where they
could enter via the bloodstream during periodontal infections, which increase in frequency during
pregnancy [23,32,33]. It has also been proposed that oral bacteria can reach the uterine and vaginal
environment through the bloodstream and may induce and/or influence the labor process. In a study
by Dasanayake et al., it was observed that specific maternal oral bacteria, namely Actinomyces naeslundii,
was associated with prematurity and lower birth weight, while others, such as lactobacilli, were linked
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with term deliveries and higher birth weight [34]. Indeed, the microbiota could have an impact on the
risk for preterm delivery, as periodontal treatment during pregnancy reduced the rate of premature
birth from 10% to 1.8% [35]. Many studies have focused on the role of the maternal vaginal [36] and
oral microbiota [37], or even the placental microbiota, in preterm delivery [38,39]. However, these
studies do not adress the possible immune mechanisms involved in premature delivery, which could
be mediated by pro-inflammatory molecules from a microbial source or by direct exposure to microbial
antigens due to bacterial translocation from bleeding gingiva, triggering an autoimmune response that
could lead to a premature delivery. Nevertheless, it is still under debate whether the microbes could
really reach the gestational cavity and, if so, whether they may have any beneficial effects for pregnancy
outcomes and future health status for neonates. Indeed, most of these studies have been performed
using culture-independent techniques of which the results are commonly affected by contamination.
However, a few studies have isolated cultivable obligated anaerobes from meconium samples [17],
which are unlikely to be a contamination during delivery. Furthermore, metabolically active bacteria
in the meconium have also been shown by RNA sequencing analysis [40]. Despite these recent results,
more studies about the presence of bacteria in the meconium, placenta and amniotic fluid are needed
in order to confirm the hypothesis of the in utero colonization.
3. Perinatal Factors Influencing Infant Microbiota Development and Immune System Maturation
Neonatal colonization is a fragile, dynamic, and step-wise process and may be affected by several
maternal and neonatal factors (Figure 1). It has been reported that the effect of perinatal factors,
including the mode of delivery, breastfeeding, and antibiotics use early in life, could influence the
microbiota composition during a short period of time [41–46]. For instance, Lactobacillus, Bifidobacterium,
Bacteroides, Clostridium, and Streptococcus, which are commonly influenced by the above-mentioned
factors, have been shown to affect the regulatory T cells activity in mice models and cell cultures [47,48].
Thus, the studies considering the effect of specific bacteria on naïve T cells differentiation [41,49] or
the influence of bacterial antigens in the T helper cells (Th) activity [50] have become crucial to assess
the impact of those factors in the neonate microbiota. Although, the alterations of the microbiota due
to perinatal and postnatal factors appear not to be maintained after neonates acquire an adult-type
microbiota, at around 3–5 years of age, these coordinated events could have long-lasting effects on
how the microbial community would influence the host immune responses [51].
3.1. Environment and Geographical Location
The environment is a natural source of microbes to the newborn that is shared with cohabiting
individuals [52], objects, and animals. Thus, neonates with siblings may have a colonization process
slightly different than children without them [53]. Regarding contact between infants and pets,
a beneficial effect on the prevention of some allergies and other immunological diseases has been
observed [54,55]; however, the molecular mechanisms behind this effect and the potential influence
of the microbiota are not clear. It has been hypothesized that rural areas, when compared with
more urban zones, could have an impact on the microbiota composition and its response to an
immunological challenge [56]. For instance, children living on farms have higher bacterial diversity [57]
and decreased risk of developing allergies [56,58]. Notably, most microbiota studies during infancy, up
to date, have been conducted in European and American populations, and information about bacterial
colonization processes in tribal communities and developing countries is still scarce. In a study, De
Filippo et al. observed that children living in rural African areas have higher intestinal bacterial
richness and diversity compared with European children, and several exclusive short-chain fatty acids
(SCFAs)-producing bacteria, whose protective role against gut inflammation has been proven [59].
Indeed, not only postnatal exposure, but also maternal exposure to this type of environment could
influence the risk of the development of allergic manifestations in offspring [8]. Therefore, it is of great
interest to understand how the microbiota may affect the epigenetics and modify the immune system
maturation during the prenatal period. It is crucial to consider the effect of factors, such as geographical
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location, diet, and lifestyle upon studying the microbiota composition, because the effect observed by
a specific factor could vary depending on the country where the study has been performed.
3.2. Mode of Delivery
The microbiota of vaginally delivered newborns resemble the maternal vaginal microbiota, which
is dominated by Lactobacillus and Prevotella species, which are likely transferred to the infant through
the birth canal [43]. Other microorganisms from the maternal gut microbiota, including members from
the Enterobacteriaceae family, such as Escherichia or Klebsiella, have also been shown to contribute
to the seeding process during vaginal birth. In contrast, neonates delivered by C-section appear
to contain microbiota similar to the maternal skin, including Staphylococcus, Corynebacterium, and
Propionibacterium [43], as well as environmental microbes [60].
Longitudinal studies comparing the influence of vaginal and C-section deliveries on an infant’s
gut microbiota have provided conflicting results. This may partly be due to the high variability of the
infant microbiota after birth and to differences in methodological procedures. Consistently, it has been
reported that vaginally born infants have a higher abundance of the Bifidobacterium genus compared
with those born by C-section, as observed during the first week of life [42,44,61]. Some studies suggest
that the differences are still maintained at three months of life [43], although other studies have not
confirmed these results [42]. Furthermore, neonates born by C-section have a delayed colonization
of the Bacteroidetes phylum, and specifically of the Bacteroides genera, during the first month of
life [41–44,62]. Other genera, specially Clostridium, have been associated with C-section deliveries [42],
although this result is less consistent among studies. It has also been speculated that this difference
could be caused by the antibiotics used in C-sections before and during the surgery and by the difficulty
of breastfeeding during the first hour of life of those infants [63].
Little is known about the effects of microbiota alteration, considering the delivery mode, in the
immune system development of the neonate. Lower levels of Th1-associated cytokines in babies
born by C-section have been observed, and this could likely reflect delayed Th1 response maturation
in these children, thus having an impact on the future capacity of immune system responses to
environmental challenges. It has also been reported that vaginally born infants harbor higher levels of
immunoglobulin (Ig)A, IgG, and IgM throughout the first year of life compared with those observed
in C-section infants [35].
Lower bacterial diversity and altered microbial composition, as observed in C-section-delivered
infants, may influence the immune system maturation process and play a role in diseases related to
an immune imbalance, including asthma [64,65] and atopic and allergic disorders [63]. However, this
relationship has been reported in observational and epidemiological cohort studies, and it is not
possible to assign a causal relation between the microbiota associated with the mode of delivery and
immune disorders.
Interestingly, animal studies have reported that vaginal delivery is associated with an early
acquisition of lipopolysaccharide (LPS) resistance, which is mediated by activation of epithelial cells
that may induce systemic immune tolerance [66]. In humans, less LPS biosynthesis was observed
to have a protective effect against asthma [67,68]. Moreover, the Bacteroides genus, and specifically
B. fragilis, could be a source of LPS and may therefore have the ability to activate regulatory T cells
upon toll-like receptor 2 (TLR2) activation by LPS surface polysaccharide A (PSA) [69]. However, not
all Bacteroides species have the same LPS types and not all of them may trigger the same immune
responses. Therefore, further mechanistic studies are needed in order to evaluate the impact of the
microbiota shift associated with C-sections in the molecular pathways of the immune system that can
influence children’s health later in life.
3.3. Antibiotics Intake during Pregnancy and Early Infancy
Antibiotics intake, along with feeding habits, is the postnatal factor that primarily influences infant
microbiota establishment. Intrapartum antibiotics prophylaxis, which is associated with C-sections,
Med. Sci. 2018, 6, 56 5 of 23
but also with some vaginal deliveries of group B streptococcus-positive mothers, has been observed to
influence the microbial colonization process of a newborn [70,71]. Similarly, antibiotics consumption
during pregnancy may affect the gestational process and the maternal and neonatal microbiota
composition [72,73].
Higher levels of Proteobacteria with a detriment in Actinobacteria species and decreased microbial
diversity have been associated with antibiotic use during the first month of life [45,46]. An effect
of antibiotic intake on the risk of obesity [55,74–76], asthma and other atopic diseases [77–79],
diabetes [80–82], and even neurocognitive outcomes [83] has been proposed. However, the impact of
long-lasting antibiotics consumption in infants is poorly understood partly due to the low frequency of
those long treatments in children. On the contrary, studies on animal models have reported reductions
of the Lactobacillus genera and segmented filamentous bacteria after antibiotic administration, resulting
in the T helper 17 cells activation in the colon [84,85]. Antibiotics also affected diversity, motility,
and toll-like receptor (TLR) expression in mice colons [86]. Furthermore, antibiotics treatment can
modify the homeostasis between bacterial, fungal, and viral microbiota components (50). For example,
antibiotics can cause the overgrowth of fungal species, particularly Candida albicans, with the induction
of mast cells and inflammatory interleukin (IL) expression, such as IL-5 or IL-13 [87].
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Figure 1. Major events occurring in immu e syste a d gut development. During regnancy, the
T helper cells of the maternal immune system are skewed towards T helper (Th)2-type immunity, to
maintain the tolerance of the developing fetus. The mother here contributes with tolerogenic mediators
through the placenta (including antibodies and growth factors), thus instructing fetal immune system
development. However, during the first weeks and months of life, infants subsequently increase
Th1 activity, thus restoring the balance of helper T cells. Without this shift, Th2 persistence might
be associated with atopic diseases including asthma. While Th cells play an important key role in
the direction of immune responses, mainly neonatally, regulatory T cells suppress the activation and
development of naïve T cells towards Th types, thus maintaining the mucosal homeostasis both during
the pregnancy and the infancy period [88].
4. Postnatal Microbial Establishment and Immune Maturation
Gut bacteria represents the key player in microbial stimulation, providing specific signals
for adequate immune stimulation and development [89]. Infant microbial colonization develops
during a critical time window, which includes the first thousand days of life [90], and that will
favor the mutualistic relationship between the host and microbiota, contributing to immunological
homeostasis. Early and diverse microbial establishment with repeated exposure to foreign microbial
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antigens (including polysaccharide A and LPS) and short-chain fatty acids would be key inthe specific
microbial species colonization and its influence on driving normal immune mucosal and systemic
maturation [89,91]. It is believed that the pioneer microbiota, consisting of Firmicutes, Bacteroidetes,
Enterobacteriaceae, Veillonella, and especially Bifidobacterium [91–94], is responsible for the initial
education of the evolving immune system, as it provides a favorable environment for further microbial
settlement, including the production of an anaerobic milieu, specific compounds, and protection
from the systemic immune system [92]. The early intestinal microbiota is characterized by low
diversity and a relative dominance of the phyla Proteobacteria and Actinobacteria. Subsequently, the
microbiota becomes more diverse, thus resembling an adult composition by 2–5 years of age [18].
However, the microbial community development and species interactions seem to be influenced by
the order and timing of species immigration to the host tissue [51]. For instance, changes in the
gut microbiota during the first months of life, such as shifting from facultative anaerobes to strict
lactic acid-producing anaerobes, might partially be a consequence of the infant’s history exposure
and the patterns of colonization from their mother [62,95]. These events suggest that a priority effect
of microbial colonization may have long-lasting consequences during the early stages of the gut
microbiota development, although the importance for the host health remains unexplored [51].
The settlement of bacteria on the surface of the gut can protect against pathogen penetration
in a process known as ‘colonization resistance’, which is of great importance for the prevention
of pathogen-induced gastrointestinal inflammation [96]. Commensal bacteria have been shown to
control potential pathogen infections by competition for nutrients, adhesion sites, pH, receptors, and
production of specific metabolites and antimicrobial peptides [97] by creating a hostile environment for
pathogen survival and establishment (for instance, lactobacilli is able to reduce local pH and produce
some anti-pathogenic compounds in the vagina).
Early Colonizers and the Immune System
It is likely that microbial colonization of the fetal gut might direct initial maturation, playing an
essential role for a balanced postnatal innate and adaptive immune system (Figure 1). However, it is still
not fully understood how the neonatal gut tissue adapts to continuous microbial exposure, but features
of the maternal breast milk (BM) are considered to direct some of these early responses to commensal
microbes [93]. Also, the neonatal immature immune system during the first period of life might also
explain its ability to accept and tolerate the microbiota establishment. The early and developing immune
system is characterized by dampened pro-inflammatory cytokine responses, resulting in a more regulatory
profile [98], which favors the establishment of the microbiota. It has been reported that early neonatal gut
exposure to commensal bacteria can also suppress cells inducing pro-inflammatory responses, such as
invariant natural killer T (iNKT) cells, thus limiting mucosal inflammation [99].
The microbial pleiotropic effect on the host includes its involvement in shaping the architecture of
the immune system (including Peyer’s patches), in regulating the balance between the immune cell
types present and in influencing the development of immune cell populations (including regulatory
T cells) [93]. Neonatal immune cells vary in function from adult ones mainly in their tolerance in
responses upon antigen exposure [91]. The two main gastrointestinal immune compartments that are
affected by the colonizing microbiota are the mucus layer and the gut-associated lymphoid tissue [93].
The mucosal barrier here is constantly in contact with the enteric inhabitants, and it is responsible for
providing a powerful and efficient protection against pathogens while at the same time sustaining the
tolerance against the normal commensals [99].
5. Commensal Recognition and Tolerogenic Features of the Gut Immune System
5.1. Intestinal Epithelial Cells
Intestinal epithelial cells (IEC) provide both a physical and chemical barrier, thus maintaining
intestinal homeostasis [100]. These cells produce various immunoregulatory signals, as a result
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of host–commensal microorganism interactions, which are essential for tolerant immune cells of
the gut, limiting the steady-state inflammation, as well as directing appropriate immune responses
against pathogens and commensal bacteria [101,102]. IEC-derived IL-25 cytokine, thymic stromal
lymphopoietin, or retinoic acid together with transforming growth factor-β are important for the
priming of adaptive immune cell responses and homeostasis, as well as for the regulation of innate
effector responses [101].
5.2. Microbial Associated Molecular Patterns and Dendritic Cells
Microbial-associated molecular patterns (MAMPs) are essential for maintaining the dialogue
between the host and the microbiota, thus promoting healthy microbial colonization [95]. Even though
neonate innate cells express TLRs (that upon stimulation in adults normally result in the production of
inflammatory mediators), their responses to microbial ligands are dominated by regulatory cytokines,
including IL-10 [103]. TLR signaling also elicits tolerogenic phenotypes of dendritic cells (DCs),
resulting in an immune response dominated by regulatory T cells [104]. DCs possess a C-type
lectin receptor that recognizes and binds to MAMPs on the microbiota, including commensal
bacteria Lactobacillus reuteri and Lactobacillus casei, thus resulting in Treg cell induction [105,106].
Moreover, Bifidobacterium infantis stimulates DCs to induce Foxp3regulatory T cellsand IL-10-secreting
T cells, and likely, each bacterium is differently sensed by DCs according to the type of pattern
recognition receptors (PRRs) with which it interacts [107,108]. Furthermore, activated DCs may also
induce Th1 responses and secrete anti-inflammatory cytokines, thus promoting intestinal mucosal
homeostasis [109,110]. Intriguingly, even though both commensals and pathogens possess MAMPs,
the commensal bacteria, including Lactobacillus spp. and Bacteroides spp., are capable of inhibiting
the Nuclear Factor Kappa Beta (NF-κB) pathway, which is important in microbial recognition and
subsequent inflammatory responses [95]. Similarly, the microbiota, specifically segmented filamentous
bacteria, regulates the upregulation of Th17 inflammatory cells, thus protecting against infections at
the mucosal surface [111].
5.3. IgA Antibody–Microbiota Interactions
A major defensive mechanism on the mucosal surface is comprised of secretory immunoglobulin
A (sIgA), which is involved in blocking the adhesion of microbes to epithelial cells without starting
any inflammatory reaction that can cause tissue damage [112]. Mucosal IgA represents the antibodies
with high affinity, neutralizing microbial toxins and invasive pathogens, and low affinity, confining
commensals in the intestinal lumen [112,113]. The involvement of the gut microbiota in instructing
sIgA is believed to occur in two ways—either by controlling the production of sIgA [114] or by
contributing to the modulation of the sIgA repertoire [112,115,116]. The production of IgA is assumed
to be modified by the uptake of luminal commensal bacteria (or their antigens) by M cells (microfold
cells incorporated among epithelial cells of the mucosal barrier) and in turn captured by DCs in
Peyer’s patches. This results in the activation and maturation of B cells in lymph nodes leading
to IgA production and thus to prevention of microbiota penetration through the mucosal barrier,
a mechanism known as a negative feedback-loop [117]. Thus, the microbiota has an impact on B
cells’ capacity to drive isotype switching [118], where for instance, mice microbiota alterations due
to large spectrum antibiotics or germ-free conditions can lead to a switch to IgE rather than IgA and
subsequent activation of basophils, mast cells. and inflammation [119]. Moreover, selected commensals
can induce systemic IgA-mediated immunity, thus constitutively protecting against bacterial sepsis
in mice models [120]. Overall, IgA might be important for diversity and balance of commensals by
controlling their expansion in the gut, which is evident in their role in gene-expression regulation of
commensals, thus selecting species that possess less inflammatory activity on the host’s tissue [121].
Intriguingly, it has been showed that intestinal IgAs are polyreactive and coat a broad but defined
subset of the microbiota [122]. This suggests that the IgA, though originating from adaptive immunity,
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have innate-like recognition characteristics that may assist the adaptation to a broad range of the
microbiota and their antigens/metabolites encountered at the mucosal surface of the gut [122].
Interestingly, the pattern of bacterial recognition by IgA in infant feces has been shown to be
aberrant during the first months of life in children that develop allergies or asthma years later. From an
applied point of view, this suggests that the IgA coating pattern with bacteria can be used as an early
diagnostic marker of allergy risk [123].
5.4. Regulatory T Cells
Although immunological tolerance in the gut is likely achieved and sustained via multiple and
redundant mechanisms [124], Foxp3 regulatory T (Treg) cells have a central role in our understanding
of this process. The evidence suggests that gut commensals, including Lactobacillus, Bifidobacterium,
Bacteroides, Clostridium, and Streptococcus [125], as well as bacterial metabolites, such as butyric acid and
propionic acid [48], may program Treg cells in the intestine [126,127]. For instance, Clostridium cluster
XIVa and Clostridium cluster IV, have been shown to affect the number and function of Foxp3+CD4+Treg
cells [128,129]. Also, Lactobacillus rhamnosus GG and/or Bifidobacterium infantis were observed to endorse
the expansion of CD4+CD25+Foxp3+Treg in the gut of mice models [130], while B. fragilis is capable of
increasing the suppressive capacity of Tregs by downregulating pro-inflammatory cytokines IL-8 and
interferon gamma (IFNγ) [131]. The induction of Treg cells is proposed as one of the mechanisms of
action of health-associated bacteria recognized to induce a health benefit to the host. However, certain
helminths directly drive Treg cell responses in the host, thus suppressing the collateral damage during
parasite infection and limiting allergic, autoimmune, and inflammatory reactions [132]. On the other
hand, helminth infections may reduce vaccine responses and increase susceptibility to coinfections
with other parasites [132].
The importance of the “healthy” gut microbiota is understood through the germ-free mice studies
where it has been revealed that the microbiota plays a critical role in lymphoid structure development.
For instance, this effect is mainly evident in the smaller size of Peyer’s patch and also a reduced amount
of CD4+ and CD8+ cells and IgA producing plasma cells [133,134]. Colonization with Bacteroides
(as B. fragilis), Clostridium, Lactobacillus and Bifidobacterium group improves various defective immune
responses observed in germ-free mice and upregulates the expression of genes involved in intestinal
development, transport and immune protective functions [133,135,136]. Gut commensals can also
contribute to the strengthening of the intestinal barrier by favoring the epithelial cell maturation and
angiogenesis, as described in mice models [135,137]. In germ-free mice, the mucus barrier thickness,
compactness, and mucin content are reduced, and the number and function of goblet cells decline [138].
6. Role of Breast Milk on Microbiota and Immunity Maturation
The most relevant post-natal factor that supports an adequate microbial colonization and
drives the immune system maturation is breastfeeding [139–141]. Compared with formula feeding,
breastfeeding has been associated with decreased morbidity and mortality in infants, and to lower
incidence of gastrointestinal infections and inflammatory, respiratory, and allergic diseases [141–144].
Breast milk is considered the gold standard nourishment for the infant, and beyond that, it also
contains a wide variety of bioactive compounds that dynamically change their composition over
time to satisfy the needs of the growing infant [145]. After delivery, when the infant host defenses
are vulnerable, BM provides protection through transference of antimicrobial and anti-inflammatory
compounds, while also stimulating the maturation of the immune system [139–146]. In addition, BM
is known to contain prebiotic compounds, as well as its own microbiota, both supplying the initial gut
colonizers and supporting the microbial succession in the infant gut [28,147,148]. Selected immune
components and microorganisms present in BM are described in Figure 2.
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6.1. Breast Milk Microbiota
Staphylococcus, Streptococcus, and Propionibacterium are universally predominant in BM [149], and
typical probiotic genera, such as Bifidobacterium and Lactobacillus [150–153], are commonly detected
and isolated from BM. Other lactic acid bacteria, such as Lactococcus, Weisella and Enterococcus, as well
as typical oral inhabitants, such as Veillonella and Prevotella, and skin bacteria, such as Propionibacterium,
Corynebacterium, and so on, are frequently detected in BM samples [154–156].
In addition, shared species between maternal feces, BM, and infant feces have been identified [157].
Although information about the function of BM bacteria is scarce, several roles have been associated
with them, including seeding colonizers to the infant microbiota, facilitating infant digestion,
offering protection by competing with pathogens, and improving intestinal barrier functions by
enhancing mucine production and reducing intestinal permeability [141]. Breast milk microbiota and
other milk molecular components likely help to educate the infant’s immune system. It promotes
an adequate intestinal immune homeostasis that initially influences a shift from an intrauterine
Th2 predominant to a Th1/Th2 balanced response and a stimulation of T-regulatory cells by BM-specific
microorganisms [158]. Furthermore, some strains isolated from BM have shown an ability to modulate
both natural and acquired immunity [152,153]. Recently, several yeasts and other fungi have been
detected in BM samples from healthy mothers, including Malassezia, Candida, Saccharomyces, and
Rhodotorula, among others. This finding suggests that BM could be not only participating in shaping the
infant microbiome, but also the infant mycobiome [159]. Future research is needed to fully understand
the role of BM microbiota in the infant, but the increasing evidence reinforces its importance on infants’
protection and training of the immune system during the first months of life.
6.2. Human Milk Oligosaccharides
One of the major protective roles of BM resides on human milk oligosaccharides (HMOs), which
are complex carbohydrates present in high concentrations in milk (5–20 g/L) [160]. Human milk
oligosaccharides are responsible for promoting the growth of beneficial commensal bacteria, such as
Bifidobacterium and Lactobacillus, which is reflected in differences observed in the intestinal microbiota of
breast-fed and formula-fed infants [148,161]. Human milk oligosaccharides are essentially indigestible
by the human gut and reach the colon where they serve as substrate for fermentation to bacteria, such
as bifidobacteria and lactobacilli and also Bacteroides and Staphylococcus, playing an important role in
shaping the infant microbiome [150,151]. This fermentation results in sub-products, such as lactate
and Short-chain fatty acids (SCFAs), including acetate and butyrate, and other metabolites. SCFAs also
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represent the main energy source for colonocytes and provide important immune protective functions.
For example, acetate stimulates the proliferation of Treg cells in the lamina propria, regulating intestinal
homeostasis [162], and several immunological functions for butyrate have been reported, many of
them associated with potent regulatory effects on gene expression [163]. Importantly, specific HMOs
can act as homologous to infant gut cell receptors, inhibiting the binding of pathogens to the intestinal
epithelium and therefore offering protection against infections [160,164].
6.3. Secretory IgA
Secretory IgA (sIgA) is the most abundant immunoglobulin in BM, with highest levels in
colostrum (12 g/L) that decrease in mature milk (0.5 g/L). It represents the key anti-infective
component in BM as it protects mucosal sites by interfering with the adherence of pathogens to
epithelial cells and neutralizes toxins [165,166]. Secretory IgA transference to the infant’s gut through
breastfeeding compensates the delay of a newborn’s innate sIgA production, and its concentration
in milk decreases as the infant’s endogenous levels increase [167]. When an enteric pathogen is
presented to a dendritic cell in the maternal intestine, activated T lymphocytes stimulate B lymphocytes,
which migrate to the mammary gland where they differentiate into plasma cells and produce large
amounts of IgA. IgA attaches to the polymeric Ig receptor and is transported through the mammary
epithelial cell, after which the complex is cleaved and sIgA is secreted to the milk [166]. In the
infant gut, sIgA provides the infant with a unique immunological protection against pathogens,
including bacteria, fungi, viruses, and parasites, to which the maternal immune system has been
exposed [148,168–170]. Levels of sIgA in milk from mothers delivering preterm are higher, showing
an adaptation of BM to increase the protection of premature infants, whose immune systems are
more susceptible to infections [171]. Recently, altered sIgA responses towards the gut microbiota
were observed in exclusively breastfed children who later in life developed allergies, meaning that
divergent antibodies/microbiota transmitted through breast milk could affect the infant’s correct
immune development [123].
6.4. Anti-Microbial Bioactive Proteins
Breast milk contains typical components of the innate immunity that are lacking in an
infant’s immature host defenses, which protect the infant while also dictating additional selection
on the infant gut microbiota. Among the broad diversity of bioactive proteins, lactoferrin,
lysozyme, and α-Lactalbumin are, together with immunoglobulins, major whey proteins that exert
immunity-enhancing properties. Lactoferrin is present in BM in high concentrations and protects the
infant against pathogens through diverse modes of action. Lactoferrin chelates free iron, a necessary
nutritional requirement for most bacterial pathogens, thus inhibiting the growth of a broad spectrum
of bacteria [172]. In addition, partial digestion of lactoferrin leads to lactoferricin, a peptide with
potent broad activity against bacteria, fungi, and viruses [173–175]. Other beneficial actions of
lactoferrin include the stimulation of pathogen phagocytosis by macrophages [176], the downregulation
of inflammatory cytokine production in monocytic cells by its interference with NF-κB protein
complex activation [177], the promotion of beneficial gut microbiota in the infant [178], and so
on. Lysozyme, although present in lower concentrations than lactoferrin, is a crucial factor of the
protective activity of BM. It breaks peptidoglycans bonds of bacterial cell walls, thus lysing pathogenic
Gram-positive bacteria, while it can also act synergistically with lactoferrin to kill Gram-negative
bacteria [179]. α-Lactalbumin is the major whey protein in BM, and some of its proteolytic fragments
have shown prebiotic properties in vitro by stimulating the growth of beneficial bifidobacteria [180].
In addition, caseins are a family of highly glycosylated proteins that constitute approximately
40% of total BM proteins. κ-Casein, a minor casein subunit in BM has been shown to act as a binding
analogue of Helicobacter pylori, inhibiting its binding to human gastric mucosa in vitro [181].
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6.5. Cytokines
Breast milk contains several cytokines at physiologically relevant concentrations, including
Interleukin (IL)-1β, IL-6, IL-8, and IL-10, especially in colostrum, which regulate and modulate
the immune system and inflammatory responses [182]. Interleukin 10, a key immunoregulatory
and anti-inflammatory cytokine, has been shown to inhibit blood lymphocyte proliferation [182].
Mutations in the encoding genes of the IL-10 receptor have been observed in infants developing
early-onset colitis, resulting in hyperinflammation of the intestine [183]. Similarly, mice with
a disrupted IL-10 gene spontaneously developed enterocolitis after weaning, and the condition
was associated with unpaired cytokine production by CD4+ Th1-like T cells, as well as activated
macrophages [184]. Intestinal inflammation could be prevented by parenteral administration of the
IL-10, thus suggesting a crucial role of BM IL-10 on the infant intestinal homeostasis and prevention
of exacerbated response to foreign antigens. Transforming growth factor (TGF-β) is associated with
the regulation of T-cell activation, but it also affects B cells, natural killer (NK) cells, macrophages,
and dendritic cells [180]. TGF-β can reduce inflammation by decreasing pro-inflammatory cytokines
production while favoring IgA production, thus increasing intestinal immunity [180]. Infants fed with
BM containing high concentrations of TGF-β, have been associated with lower risk of developing
atopic diseases and wheezing [185,186].
6.6. Cells and Other Immunological Compounds
Leukocytes. Activated live leukocytes are present in BM, including macrophages (40–50% of total
leukocytes), polymorphonuclear neutrophils (40–50% of total leukocytes), and lymphocytes (5–10% of
total leukocytes) [187]. Leukocytes concentrations are the highest in colostrum and decrease gradually.
If the mother or infant suffers an infection, leukocytes levels can increase to 97% of the total cells in
BM [188]. The lymphocytes population consists mainly of T cells (approximately 80%), where most
of them are activated, motile, and interactive, thus suggesting that they confer active immunity to
the infant. In addition, leukocytes, particularly polymorphonuclear, offer protection to the mammary
gland under mastitis infections [189].
Soluble CD14 (sCD14). sCD14 is a pattern recognition receptor, which together with toll-like
receptor 4 (TLR4) and LPS-binding protein forms the lipopolysaccharide (LPS)-recognition complex
that binds bacterial LPS. It participates in the signal transduction initiation of TLR-4, which results
in a high secretion of IL-12, a pro-inflammatory cytokine. sCD14 has been suggested to be an
important immune modulator for intestinal homeostasis and may play an important role in the
infant’s intestinal defense [190]. Moreover, this protein has been associated with lower risk for asthma
in early childhood [191].
Glycosylated proteins. Certain glycosylated proteins, such as strongly glycosylated BM mucins,
can interfere with bacterial and viral adherence to the gut epithelium. Mucin-1 (MUC1) is the
predominant mucin in BM, present in the surface of fat globules, and inhibits the binding of pathogens
to the mucosal epithelia [191], including pathogenic bacteria, such as H. pylori and rotavirus, which
represent the main cause of acute gastrointestinal infectious in infants [192].
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7. Concluding Remarks
The maturation of the immune system is accomplished through bidirectional interactions where
the gut microbiota directs the development of the immune system, while the host immune system
shapes the establishment of the gut microbiota. Even though current studies are attempting to associate
specific microbes to unique immunological states, it is worth remembering that the microbiome is
a highly dynamic, diversified, and complex human organ, where all the composing microbes are
expressing a vast number of potential ligands and metabolites. Under normal homeostatic conditions,
both inflammatory and regulatory features are highly balanced, thus leading to the establishment of
stable tissue immunity and limited inflammation. Hence, upon alterations within the microbiota that
may cause an inflammatory state, it is unlikely that the outcome observed is due to a single microbial
product, but rather a result from a shifted balance state of an entire community.
Several prenatal and perinatal factors, including the mode of delivery, antibiotics consumption,
diet, and other environmental factors, may influence the microbial colonization of the infant and
in turn its immune system maturation. Here, breast milk plays an essential role, guiding a normal
microbiome development in the infant through transference of prebiotic compounds that support
the colonization of beneficial bacteria and antimicrobial components that protect the infant against
infections. Breast milk microbiota should also be considered as an important source of microorganisms
to the infant microbiomes and as part of microbial tolerance and immune training in the child.
In addition, BM contains several bioactive and immunomodulatory compounds, which together
with immune cells and microorganisms support the infant’s protection when its immune system is
still immature (Figure 3). Most of the existing literature is focused on the role of bacteria, but more
studies need to elucidate the importance of archaea, fungi, and non-pathogenic viruses that also may
be important for early gut immunity maturation. Finally, the molecular mechanisms involved in the
interactions between early life microbiota and the immune system are still to be clarified.
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Figure 3. Key factors influencing microbiota development and maturation of the immune system in early life. BM: breast milk; and HMO: human milk oligosaccharides.
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